Shanghai Henlius Biotech, Inc. (HKG:2696)
Hong Kong · Delayed Price · Currency is HKD 78.15
+2.95 (3.92%)
May 7, 2026, 4:08 PM HKT
Shanghai Henlius Biotech Revenue
In the year 2025, Shanghai Henlius Biotech had annual revenue of 6.67B CNY with 16.46% growth. Shanghai Henlius Biotech had revenue of 3.85B in the half year ending December 31, 2025, with 32.91% growth.
Revenue
6.67B CNY
Revenue Growth
+16.46%
P/S Ratio
5.51
Revenue / Employee
1.77M CNY
Employees
3,762
Market Cap
40.87B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 6.67B | 942.18M | 16.46% |
| Dec 31, 2024 | 5.72B | 329.54M | 6.11% |
| Dec 31, 2023 | 5.39B | 2.18B | 67.82% |
| Dec 31, 2022 | 3.21B | 1.53B | 91.07% |
| Dec 31, 2021 | 1.68B | 1.09B | 186.34% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| 3SBio | 19.69B |
| Genscript Biotech | 7.47B |
| RemeGen | 3.84B |
| Zai Lab | 3.58B |
| Shanghai Junshi Biosciences | 3.10B |
| InnoCare Pharma | 2.87B |
| Duality Biotherapeutics | 2.06B |
| Biocytogen Pharmaceuticals (Beijing) | 1.78B |
Shanghai Henlius Biotech News
- 3 months ago - Shanghai Henlius Biotech Transcript: 44th Annual J.P. Morgan Healthcare Conference - Transcripts